# EDGAR Filing Document

**Accession Number:** 0001402328
**File Stem:** 0001683168-23-002060
**Filing Date:** 2023-3
**Character Count:** 5863
**Document Hash:** 4a5cd0880554db930f027cc61e5d0a2d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-23-002060.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001683168-23-002060

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**EFFECTIVENESS DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sunshine Biopharma, Inc
- **CENTRAL INDEX KEY:** 0001402328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 205566275
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41282
- **FILM NUMBER:** 23786651

**BUSINESS ADDRESS:**
- **STREET 1:** 6500 TRANS-CANADA HIGHWAY
- **STREET 2:** 4TH FLOOR
- **CITY:** POINTE-CLAIRE
- **STATE:** A8
- **ZIP:** H9R 0A5
- **BUSINESS PHONE:** 514-426-6161

**MAIL ADDRESS:**
- **STREET 1:** 6500 TRANS-CANADA HIGHWAY
- **STREET 2:** 4TH FLOOR
- **CITY:** POINTE-CLAIRE
- **STATE:** A8
- **ZIP:** H9R 0A5

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mountain West Business Solutions, Inc
- **DATE OF NAME CHANGE:** 20071030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** mountain west business solutions,inc
- **DATE OF NAME CHANGE:** 20070607

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

(Check One) [X] Form 10-K [_] Form 20-F [_] Form 11-K [_] Form 10-Q [_] Form 10-D [_] Form N-CEN<br> [_] Form N-CSR

For Period Ended: December 31, 2022

[_] Transition Report on Form 10-K

[_] Transition Report on Form 20-F

[_] Transition Report on Form 11-K

[_] Transition Report on Form 10-Q

For the Transition Period Ended: ________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.<br> **Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**<br>

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

---

| |
|:---|
| Sunshine Biopharma, Inc. |
| Full Name of Registrant |
| Former Name if Applicable |
| 6500 Trans-Canada Highway, 4<sup>th</sup> Floor |
| Address of Principal Executive Office *(Street and Number)* |
| Point-Claire, Quebec, Canada H9R 0A5 |
| City, State and Zip Code |

---

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

⌧ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Management requires additional time to compile data to furnish to its professionals to complete the Form 10-K for the fiscal year ended December 31, 2022.

(Attach extra Sheets if Needed)

**PART IV — OTHER INFORMATION**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Name and telephone number of person to contact in regard to this notification.

<u>Andrew I. Telsey</u> <u>(303)</u> <u>521-7447</u> <br> (Name) (Area Code) (Telephone Number)

&nbsp;&nbsp;&nbsp;&nbsp;(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant
was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

&nbsp;&nbsp;&nbsp;&nbsp;(3) Is it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statement to be included in the subject report or portion thereof?

Yes ☒ No ☐

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>SUNSHINE BIOPHARMA, INC.</u> 

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: March 31, 2023 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; By: <u>/s/Steve N. Slilaty</u> <br> Steve N. Slilaty, Chief Executive Officer |

---

SUNSHINE BIOPHARMA INC.

ATTACHMENT TO FORM 12b-25

Sunshine Biopharma Inc. anticipates that its annual revenue will increase significantly from $228,426 in 2021, to over $4 million, as a result of its acquisition of Nora Pharma Inc. on October 20, 2022. The Company's consolidated financial statements for its fiscal year ended December 31, 2022 will include the results of operations of Nora Pharma Inc. from October 20, 2022 through December 31, 2022.